Certified by Founder Lodge
Pfizer
United States - New York, New York
INVESTOR
1 Disclosed Funding Rounds $125,000,000
16 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
Breakthroughs That Change Patients' Lives: Pfizer is a leading research-based biopharmaceutical company. We apply science and our global resources to deliver innovative therapies that extend
Company | Date | Round | Raised |
---|---|---|---|
Nimbus Therapeutics | September, 13 ,2022 | Unknown | $125,000,000 |
VitaDAO | February, 15 ,2023 | Unknown | $4,100,000 |
Mediar Therapeutics | March, 15 ,2023 | Unknown | $105,000,000 |
Flare Therapeutics | March, 23 ,2023 | Series B | $123,000,000 |
Vedanta Biosciences, Inc. | April, 26 ,2023 | Unknown | $106,500,000 |
Mozart Therapeutics, Inc | June, 08 ,2023 | Series A | $25,000,000 |
Crossbow Therapeutics, Inc | July, 12 ,2023 | Series A | $80,000,000 |
CellCentric | July, 24 ,2023 | Unknown | $25,000,000 |
ReCode Therapeutics | September, 20 ,2023 | Series B | $50,000,000 |
RefleXion Medical | November, 17 ,2023 | Unknown | $105,000,000 |
Curve Therapeutics | February, 28 ,2024 | Series A | $51,183,495 |
Mission Therapeutics | March, 15 ,2024 | Unknown | $32,101,650 |
Capstan Therapeutics | March, 21 ,2024 | Series B | $175,000,000 |
Grey Wolf Therapeutics | May, 23 ,2024 | Series B | $50,000,000 |
Enara Bio | October, 04 ,2024 | Series B | $32,500,000 |
TRexBio | November, 14 ,2024 | Series B | $84,000,000 |